-transparent.png){kind=logo}
17 patients (age 15-58 years) with refractory acute leukaemia (14 AML, 3 ALL) were treated with high dose cytosine arabinoside (AraC) at a dose of 3000 mg/m2, twice daily for 6 d (13 patients with AraC alone, 4 patients with AraC and doxorubicin). 9 patients achieved complete remission (53%) and 2 a partial remission. Although sophisticated isolation and blood banking facilities are required during the pancytopenic period, the toxicity of this treatment was acceptable. Vomiting, headache, somnolence, fever, conjunctivitis and cardiac arrhythmias were found most frequently. The unexpected pulmonary failure in 3 patients was worrisome. The duration of remissions was from 1 to 12 months. Results obtained with high dose AraC are satisfactory and hold promise for the treatment of patients with previously untreated AML.
R Willemze, and
F E Zwaan, and
G Colpin, and
J J Keuning
October 1979,
Cancer,
R Willemze, and
F E Zwaan, and
G Colpin, and
J J Keuning
December 1984,
[Rinsho ketsueki] The Japanese journal of clinical hematology,
R Willemze, and
F E Zwaan, and
G Colpin, and
J J Keuning
January 1989,
Cancer chemotherapy and pharmacology,
R Willemze, and
F E Zwaan, and
G Colpin, and
J J Keuning
March 1997,
Blood reviews,
R Willemze, and
F E Zwaan, and
G Colpin, and
J J Keuning
November 2011,
Annals of hematology,
R Willemze, and
F E Zwaan, and
G Colpin, and
J J Keuning
June 1987,
Taiwan yi xue hui za zhi. Journal of the Formosan Medical Association,
R Willemze, and
F E Zwaan, and
G Colpin, and
J J Keuning
December 1989,
Bone marrow transplantation,
R Willemze, and
F E Zwaan, and
G Colpin, and
J J Keuning
January 1987,
Gan to kagaku ryoho. Cancer & chemotherapy,
R Willemze, and
F E Zwaan, and
G Colpin, and
J J Keuning
August 1988,
Cancer,
R Willemze, and
F E Zwaan, and
G Colpin, and
J J Keuning
January 1982,
Medical and pediatric oncology,
